x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2015

0,800
© Thomson Reuters, Journal Citation Reports, 2015

Indexada en:

SCIE/Journal of Citation Reports, Index Medicus/Medline, Excerpta Medica/EMBASE, SCOPUS, CANCERLIT, IBECS

Métricas

  • Factor de Impacto: 0,800(2015)
  • 5-años Factor de Impacto: 0,753
  • SCImago Journal Rank (SJR):0,23
  • Source Normalized Impact per Paper (SNIP):0,264
doi: 10.1016/j.gastrohep.2010.05.009
Letter to the Editor
Rectal bleeding and diarrhea caused by bortezomib-induced colitis
Sangrado rectal y diarrea causados por colitis asociada a bortezomib
Oscar Nogales Rincón, , Alain Huerta Madrigal, Beatriz Merino Rodriguez, Cecilia González Asanza, Enrique Cos Arregui, Pedro Menchén Fernández-Pacheco
Department of Gastroenterology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Recibido 09 mayo 2010, Aceptado 29 mayo 2010

Diarrhea is a common side effect of bortezomib. The pathogenesis of this unpredictable complication is unclear. Up until now, it was believed that this agent does not induce direct mucosal damage, with few reports of colon mucositis in the literature in recent years.1,2

We report the case of a 65-year-old man with history of multiple myeloma (IgD) who presented with acute bloody diarrhea. The patient was under treatment with melphalan and prednisone, and due to progression of his disease, recently started bortezomib (a proteosome inhibitor) 1.3mg/m2 by intravenous bolus injection on days 1, 4, 8 and 11, to be repeated every 3 weeks. Bloody diarrhea started 24h after the fourth dose of bortezomib and was not accompanied by mucus or fever; the patient referred an autolimited non-bloody diarrhea after the third dose of bortezomib. Laboratory tests showed a previously unknown plaquetopenia (58.000plaq/μL (140.000–400.000plaq/μL). The emergency sigmoidoscopy revealed multiple ecchymosis and small colonic ulcers covered by fibrin and perilesional inflammation with a trend to stenose the lumen (Fig. 1a, b). Biopsy specimens showed a normal epithelium with a chronic and unspecific inflammatory infiltrate in the crypts (Fig. 2) with lack of amiloyd or clonicity of Kappa/Lambda chains; the bacterial and viral cultures were negative. Bloody diarrhea and plaquetopenia disappeared after the suspension of bortezomib, without new episodes after 6 months under treatment with melphalan, prednisone and talidomide.

Figure 1.

(a and b) Small colonic ulcers covered by fibrin and perilesional inflammation with a trend to stenose the lumen.

Figure 2.

Normal epithelium with a chronic and unspecific inflammatory infiltrate in the crypts.

Frequent watery diarrhea following bortezomib is oftenly related to other mechanisms rather than mucositis. However, a more intense surveillance of patients under this treatment could be justified to exclude more severe pathology.

References
1
A. Siniscalchi,A. Tendas,M. Ales,S. Fratoni
Bortezomib-related colon mucositis in a multiple myeloma patient
Support Care Cancer, 17 (2009), pp. 325-327
2
V. Perfetti,G. Palladini,L. Brunetti
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor
Eur J Gastroenterol Hepatol, 19 (2007), pp. 599-601
Corresponding author.
Copyright © 2010. Elsevier España, S.L.